<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043597</url>
  </required_header>
  <id_info>
    <org_study_id>LHD Thrombus aspiration</org_study_id>
    <nct_id>NCT05043597</nct_id>
  </id_info>
  <brief_title>Effectiveness Evaluation in Thrombus Aspiration in Patients With STEMI and High Thrombotic Load</brief_title>
  <official_title>Effectiveness Evaluation in Thrombus Aspiration in Patients With STEMI and High Thrombotic Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to evaluate thrombus on the basis of different methods for evaluating&#xD;
      thrombus load The effect of aspiration on the prognosis of STEMI patients with high&#xD;
      thrombotic load Provide a basis for the standardized use of aspiration; at the same time,&#xD;
      discover the best benefit groups for thrombus aspiration&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse cardiovascular events</measure>
    <time_frame>3 years</time_frame>
    <description>Including cardiogenic death, recurring myocardial infarction Stent thrombosis or target vessel revascularization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3838</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Thrombus aspiration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thrombus aspiration</intervention_name>
    <description>Thrombus aspiration</description>
    <arm_group_label>Thrombus aspiration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Age ≥ 18 years; (2) Voluntary signing of informed consent; (3) Onset of 12 hours&#xD;
             STEMI patients who underwent PCI reperfusion therapy within time; (4) The guidewire&#xD;
             passes through the lesion and the blood Heavy embolism load (TIMI thrombus&#xD;
             classification ≥ 3).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Hemodynamics is unstable or there is cardiogenic shock; (2) After thrombolytic&#xD;
             therapy; (3) The expected survival time is less than 6 months due to non-cardiac&#xD;
             diseases; (4) Past trips Coronary artery bypass graft patients; (5) Participate in&#xD;
             other drug and device research within 30 days; (6) Before surgery, clear active&#xD;
             gastrointestinal bleeding or other contraindications for taking dual antiplatelet&#xD;
             drugs (7) Patients deemed unsuitable for enrollment by other researchers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

